NOTE: The 3 largest psychedelic drug stocks in the sector were down 5.3% for the week ending Thursday compared to -1.5% the previous week. They are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M, since their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their performances for the week ending Thursday with the previous week's performances in brackets:

1. Compass (CMPS) -3.4% (-0.07%)
2. Field Trip (FTRPF) -20.5% (+12.0%)
3. MindMed (MMEDF) -16.2% (+1.4%)

The remaining 13 stocks in this fledgling, yet burgeoning, sector were down -1.6%, on average, for the week ending Thursday compared to +7.8% the previous week. They are not eligible for inclusion in the munKNEE Psychedelic Stocks Index but are worth watching closely (see a previous article on the subject here) with the sector starting to gain considerable traction. They are as follows:

Aion (CSE: AION), Codebase (BKLLF), Ehave (EHVVF), Graph Blockchain  (REGRF), Lobe Sciences (GTSIF), New Wave (TRMNF), Thoughtful Brands (PEMTF), Entheon (ENTBF), Core One (CLABF), Newscope-PharmaTher (CSE: PHRM), Nutritional High (SPLIF), Pure Extracts (CSE: PULL) and Tryp Therapeutics (CSE: TRYP).

Please note that Minerco (MINE) has been removed from the list as it is trading below $0.01/share on very spotty volume and Tryp Therapeutics (CSE: TRYP), which was listed earlier this month, has been added.